Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 44


Management of Diabetes Associated with Nephrotic Syndrome: Therapeutic Potential of Dapagliflozin for Protracted Volume Retention.

Imai T, Akimoto T, Ito C, Masuda T, Nagata D.

Drug Target Insights. 2015 Nov 11;9:29-31. eCollection 2015.


SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.

Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero RM, Woerle HJ, Broedl UC, Johansen OE.

Diab Vasc Dis Res. 2015 Mar;12(2):90-100. doi: 10.1177/1479164114559852. Epub 2015 Jan 14.


Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans.

Lu Y, Griffen SC, Boulton DW, Leil TA.

Front Pharmacol. 2014 Dec 10;5:274. doi: 10.3389/fphar.2014.00274. eCollection 2014.


Dapagliflozin for the treatment of type 2 diabetes: a review of the literature.

Saeed MA, Narendran P.

Drug Des Devel Ther. 2014 Dec 10;8:2493-505. doi: 10.2147/DDDT.S50963. eCollection 2014.



Cada DJ, Levien TL, Baker DE.

Hosp Pharm. 2014 Jul;49(7):647-62. doi: 10.1310/hpj4907-647.


Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options.

Du YF, Ou HY, Beverly EA, Chiu CJ.

Clin Interv Aging. 2014 Nov 18;9:1963-80. doi: 10.2147/CIA.S53482. eCollection 2014. Review.


SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes.

Moses RG, Colagiuri S, Pollock C.

Australas Med J. 2014 Oct 31;7(10):405-15. doi: 10.4066/AMJ.2014.2181. eCollection 2014. Review.


Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model.

Demin O Jr, Yakovleva T, Kolobkov D, Demin O.

Front Pharmacol. 2014 Oct 13;5:218. doi: 10.3389/fphar.2014.00218. eCollection 2014.


Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study.

Kaku K, Maegawa H, Tanizawa Y, Kiyosue A, Ide Y, Tokudome T, Hoshino Y, Yang J, Langkilde AM.

Diabetes Ther. 2014 Dec;5(2):415-33. doi: 10.1007/s13300-014-0086-7. Epub 2014 Oct 24.


SGLT2 inhibitors act from the extracellular surface of the cell membrane.

Ghezzi C, Hirayama BA, Gorraitz E, Loo DD, Liang Y, Wright EM.

Physiol Rep. 2014 Jun 27;2(6). pii: e12058. doi: 10.14814/phy2.12058. Print 2014 Jun 1.


Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.

Riggs MM, Seman LJ, Staab A, MacGregor TR, Gillespie W, Gastonguay MR, Woerle HJ, Macha S.

Br J Clin Pharmacol. 2014 Dec;78(6):1407-18. doi: 10.1111/bcp.12453.


Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial.

Strojek K, Yoon KH, Hruba V, Sugg J, Langkilde AM, Parikh S.

Diabetes Ther. 2014 Jun;5(1):267-83. doi: 10.1007/s13300-014-0072-0. Epub 2014 Jun 12.


Patient considerations in the management of type 2 diabetes - critical appraisal of dapagliflozin.

Salvo MC, Brooks AD, Thacker SM.

Patient Prefer Adherence. 2014 Apr 22;8:493-502. doi: 10.2147/PPA.S59169. eCollection 2014. Review.


Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus.

Reilly TP, Graziano MJ, Janovitz EB, Dorr TE, Fairchild C, Lee F, Chen J, Wong T, Whaley JM, Tirmenstein M.

Diabetes Ther. 2014 Jun;5(1):73-96. doi: 10.1007/s13300-014-0053-3. Epub 2014 Jan 29.


A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment.

van der Walt JS, Hong Y, Zhang L, Pfister M, Boulton DW, Karlsson MO.

CPT Pharmacometrics Syst Pharmacol. 2013 May 8;2:e42. doi: 10.1038/psp.2013.20.


Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes.

DeFronzo RA, Hompesch M, Kasichayanula S, Liu X, Hong Y, Pfister M, Morrow LA, Leslie BR, Boulton DW, Ching A, LaCreta FP, Griffen SC.

Diabetes Care. 2013 Oct;36(10):3169-76. doi: 10.2337/dc13-0387. Epub 2013 Jun 4.


First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.

Kapur A, O'Connor-Semmes R, Hussey EK, Dobbins RL, Tao W, Hompesch M, Smith GA, Polli JW, James CD Jr, Mikoshiba I, Nunez DJ.

BMC Pharmacol Toxicol. 2013 May 13;14:26. doi: 10.1186/2050-6511-14-26.


Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.

Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J.

Diabetes Obes Metab. 2013 Sep;15(9):853-62. doi: 10.1111/dom.12127. Epub 2013 Jun 5.


Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.

Hussey EK, Kapur A, O'Connor-Semmes R, Tao W, Rafferty B, Polli JW, James CD Jr, Dobbins RL.

BMC Pharmacol Toxicol. 2013 Apr 30;14:25. doi: 10.1186/2050-6511-14-25.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk